Study of HAllucinations in Parkinson's disease, Eye disease, and Dementia- Trial Feasibility (a randomised controlled 2-stage interventional trial

King's College London0 个研究点目标入组 10 人开始时间: 2018年1月30日最近更新: 2019年4月8日

试验速览

暂无简介。

•1. 60+ years old
•2. Sufficient fluency in English to participate in the interviews
•3. Clinical diagnosis of dementia, eye disease or Parkinson’s disease.
•4. Experience of visual hallucinations every two weeks over the 4 weeks prior to trial entry.
•5. MMSE > 13

•Exclusion Phase 1
•1. Visual hallucinations accounted for by schizophrenia, epilepsy or narcolepsy
•2. Participation in an interventional clinical trial in the previous 28 days.
•3. Patients with dementia without a study partner.
•Exclusion Phase 2
•1. If prescribed a cholinesterase inhibitor as part of routine clinical care, contraindications or cautions to ondansetron (Congenital long QT syndrome; Adenotonsillar surgery; subacute intestinal obstruction; susceptibility to QT-interval prolongation (including electrolyte disturbances - see current summary of Product Characteristics)).
•2. If not prescribed a cholinesterase inhibitor as part of routine clinical care, contra-indications or cautions to donepezil (Asthma; chronic obstructive pulmonary disease; sick sinus syndrome; supraventricular conduction abnormalities; susceptibility to peptic ulcers - see current Summary of Product Characteristics).

发起方